Heron Therapeutics posts preliminary 2025 results

Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025.

Rhea-AI Filing Summary

Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025. The company furnished this press release as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is being provided for informational purposes and is not treated as formally filed for liability purposes under Section 18 of the Exchange Act. The company also notes that this information will only be incorporated into other securities filings if specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Heron Therapeutics (HRTX) disclose in this 8-K filing?

Heron Therapeutics disclosed that it issued a press release announcing its preliminary financial results for the three months ended December 31, 2025 and the full year 2025, which is furnished as Exhibit 99.1.

Which period do the preliminary results for Heron Therapeutics (HRTX) cover?

The preliminary results cover the three months ended December 31, 2025 and the full year 2025.

How is the Heron Therapeutics (HRTX) press release treated under securities laws?

The press release attached as Exhibit 99.1 is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless specifically referenced.

Where can investors find the preliminary 2025 results for Heron Therapeutics (HRTX)?

Investors can find the preliminary 2025 results in the press release identified as Exhibit 99.1 to this report.

Which executive signed the Heron Therapeutics (HRTX) 8-K related to preliminary 2025 results?

The report was signed on behalf of Heron Therapeutics, Inc. by Ira Duarte, Executive Vice President and Chief Financial Officer.

Under which 8-K item did Heron Therapeutics (HRTX) furnish its preliminary 2025 results?

Heron Therapeutics furnished its preliminary 2025 results under Item 7.01, Regulation FD Disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 01:08 PM EST Learn about SEC filing dates

false000081803300008180332026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33221		94-2875566
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

100 Regency Forest Drive, Suite 300, Cary, NC		27518
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (858) 251-4400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		HRTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 9, 2026, the Company issued a press release announcing its preliminary financial results for the three months ended December 31, 2025 and full year 2025. A copy of the press release is furnished as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Heron Therapeutics, Inc.
Date: January 9, 2026			/s/ Ira Duarte
			Ira Duarte Executive Vice President, Chief Financial Officer